Ovarian Cancer | Clinical

High-Grade Ovarian Cancer Shows Survival Gap Between HR-Deficient and Proficient BRCA+ Tumors

June 11, 2021

In an interview with Targeted Oncology, held during the 2021 ASCO Annual Meeting, Travis Sims, MD, MPH, discussed the treatment of HRD-positive ovarian cancer and the retrospective analysis of HRD status and its impact of survival outcomes for this patient population.

Survival Benefit Not Improved With Extended Bevacizumab Treatment in Ovarian Cancer

June 07, 2021

Data from the phase 3 AGO-OVAR 17/BOOST/GINECO OV118/ENGOT Ov-15 trial of patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer show that even though prolonged treatment with bevacizumab is feasible and safe, it does not improve survival.

Mirvetuximab Soravtansine Combination Elicits Durable Responses in Recurrent, Platinum Agnostic Ovarian Cancer

June 07, 2021

Results from the final analysis of the phase 1b FORWARD II trail, show that mirvetuximab soravtansine combined with bevacizumab yielded durable responses in patients with recurrent, platinum agnostic ovarian cancer, a population with an unmet need for more effective, non-platinum treatments.